Drug intelligence / Profile preview

MOD-E

Development stage: Preclinical
Lead developer: Alivexis
Modality: Small Molecules

Overview

MOD-E is a small-molecule inhibitor of diacylglycerol kinase alpha (DGKα) currently under development by Alivexis as a cancer immunotherapy. DGKα is an enzyme that converts diacylglycerol (DAG) into phosphatidic acid (PA); since DAG is a key secondary messenger for T-cell receptor signaling, its depletion by DGKα leads to T-cell anergy. By inhibiting DGKα, MOD-E aims to restore and enhance T-cell activation and effector function within the immunosuppressive tumor microenvironment. Preclinical data suggests that MOD-E may act synergistically with anti-PD-1 antibodies to improve anti-tumor efficacy. The program is currently in the final preclinical stage, focused on clinical candidate identification.

Other names: Alivexis DGKα inhibitor

Targets

DGKA (Diacylglycerol kinase alpha)

Beyond the preview

Go deeper on MOD-E.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOD-E.

Explore the full profile